The aim of the study was to evaluate risk factors for mortality, including health care insurance status, among patients with AIDS in the era of modern combination antiretroviral therapy (cART).
Introduction
Mortality among HIV-infected persons decreased dramatically with the introduction of modern combination antiretroviral therapy (cART) [1] [2] [3] [4] [5] [6] . Although lower than in the era before cART, mortality remains higher than that among comparably aged HIV-uninfected persons, largely as a consequence of an increase in common agerelated, noninfectious chronic diseases that occur among HIV-infected persons [7] [8] [9] [10] [11] . Although traditional HIVrelated risk factors for mortality, such as the level of plasma HIV RNA (HIV viral load) and CD4 T-lymphocyte cell count, are well established, other socio-demographic factors are less so. The HIV Outpatient Study (HOPS) suggested that mortality was greater among cART-treated, Correspondence: Dr Douglas A. Jabs, Department of Ophthalmology, Icahn School of Medicine, One Gustave L. Levy Place, Box 1183, New York, NY 10029, USA. Tel: 212 241 6752; fax: 212 241 5674; e-mail: douglas.-jabs@mssm.edu virally suppressed, HIV-infected persons with public health insurance compared with persons with private insurance, and that public insurance may be a marker for chronic noninfectious, age-related comorbidities [12] . We evaluated risk factors for mortality in the Longitudinal Study of the Ocular Complications of AIDS (LSOCA).
Patients and methods
The LSOCA is a prospective, multicentre, observational study of patients with AIDS conducted in the era of modern cART [13, 14] . Eligible participants were aged 13 years or older and had a diagnosis of AIDS according to the Centers for Disease Control and Prevention 1993 revised surveillance case definition [15] . Enrolment occurred between 1 September 1998 and 31 July 2011; follow-up continued until 31 July 2013. The study and its procedures were approved by the institutional review boards of the clinical and resource centres and adhered to the principles of the Declaration of Helsinki. All participants gave written, informed consent.
Enrolment data collection included demographic information, medical history (including a complete medication history), nadir CD4 T-cell count prior to enrolment, maximum HIV viral load prior to enrolment, an estimate of the Karnofsky performance score, and a complete ophthalmological examination for the presence of cytomegalovirus (CMV) retinitis [13, 14, 16] . Standard 60°retinal photographs were taken and graded at a reading centre [13, 14, 17] . Laboratory measurements at enrolment included a complete blood count, CD4 T-cell count, plasma HIV viral load, and hepatitis C virus (HCV) antibody status [13, 14, 18] . Elements of the history were verified by checking medical records. Insurance status was classified as private insurance, Medicare, Medicaid, Civilian Health and Medical Program of Uniformed Services (CHAMPUS) or Veterans' Hospital coverage, and uninsured. In the USA, Medicare is a federally funded programme for elderly and disabled people, Medicaid is a federally and state-funded programme for low-income individuals, administered by the individual states, and private insurance is provided by commercial companies and purchased most often by employers (as a benefit) or by individuals. Because of the small number of participants with CHAMPUS (n = 10) or Veterans' Administration coverage (n = 15), they were excluded from the analyses; four participants had no insurance data collected. Patients with private insurance and Medicare or Medicaid (n = 153) were classified as having private insurance, and patients with both Medicare and Medicaid (n = 358) were classified as having Medicare. Sensitivity analyses classifying these participants with more than one type of insurance as separate groups gave qualitatively similar results (data not shown). cART was defined as: any three-drug regimen including a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or a fusion, integrase, or entry inhibitor or a regimen with similar efficacy, such as triple nucleoside reverse transcriptase inhibitor therapy, or dual boosted protease inhibitor therapy [6, 19] . Non-AIDS comorbidities were ascertained from the medical history and current medication log. The Karnofsky performance score was estimated by the enrolling physician and was graded between 100 (perfect health) and 0 (death) in 10-point decrements. A score of 80 points corresponds to a health status of "normal activity with effort; some signs and symptoms of disease" [16] . Measurements of CD4 T cells and HIV viral load were performed at the individual clinical centres using standard assays, and HCV antibody measurements were performed at a central laboratory on cryopreserved plasma specimens [18] .
Characteristics of CMV retinitis lesions were determined from retinal photographs graded at the reading centre by trained graders masked to other participant clinical features and outcomes, as previously described [6, 13, 14, 17, [20] [21] [22] [23] [24] . Best corrected visual acuity was measured after standardized refraction using logarithmic visual acuity charts [13, 14, 17, 24] . Visual impairment was defined as a best corrected acuity of worse than 20/40; and bilateral visual impairment was defined as best corrected acuity worse than 20/40 in both eyes [25, 26] .
Follow-up visits occurred every 3 months for patients with an ocular opportunistic infection (e.g. CMV retinitis) and every 6 months for all others until 2008 when follow-up became every 6 months for all participants. Mortality data were collected on an ongoing basis with confirmation of death obtained from death certificates or the National Death Index. Use of the National Death Index permitted mortality data to be obtained for participants lost to follow-up.
Statistical analyses
Variables were categorized using biologically meaningful cut-offs, or medians and quartiles. Comparisons of insurance status with enrolment characteristics were made using the Pearson v 2 test for categorical variables and the KruskalÀWallis test for continuous variables [27] . Follow-up time was calculated as the time from study enrolment until death, loss to follow-up, or administrative censoring. In order to anchor data to a biologically meaningful date, and to account for the duration of AIDS prior to enrolment, survival analyses were performed using staggered entries anchored at the AIDS diagnosis date [28, 29] . Analyses using only study follow-up time and adjusting for duration of AIDS, and not using staggered entries, produced similar results (data not shown). Cox proportional hazard regression was used to estimate hazard ratios (HRs) for death [30] . Models were both unadjusted and adjusted for demographic data and known risk factors for mortality in patients with AIDS (e.g. cART use, CD4 count, plasma HIV viral load, and CMV disease). Because weight at enrolment was a predictor of mortality and had an 11% missing rate, multiple imputation was used for the time-independent regression analyses adjusting for weight. Observations with missing weight at enrolment were imputed using five data sets.
The imputation model included all baseline covariates. Statistical analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC, USA) and STATA release 13 (StataCorp, College Station, TX, USA).
Results

Characteristics of the study population
There were 2392 participants enrolled in LSOCA, of which 2363 were included in these analyses. Enrolment characteristics of the study population by insurance status are presented in Table 1 
Mortality
Mean follow-up was 7.75 years, during which there were 733 deaths, resulting in a mortality rate of 4.0/100 person-years (PY). Mortality was greater among publicly insured participants, both those with Medicare and those with Medicaid ( Fig. 1 and Table 2 ), compared with privately insured persons. Unadjusted HRs for mortality were 1.54 [95% confidence interval (CI) 1.28-1.86; P < 0.001] for Medicare and 1.36 (95% CI 1.11-1.66; P = 0.003) for Medicaid. Uninsured participants' unadjusted HR for mortality was 1.00 (95% CI 0.79-1.28; P = 0.97) compared with privately insured participants. Adjustment for enrolment characteristics attenuated these differences (Table 3) . Adjusted HR (HR adj ) values for mortality were 1.35 (95% CI 1.08-1.67; P = 0.008) for participants with Medicare and 1.21 (95% CI 0.94-1.55; P = 0.14) for those with Medicaid vs. privately insured participants. Participants uninsured at enrolment were not significantly different from privately insured participants (HR adj 0.89; 95% CI 0.68-1.18; P = 0.42).
Other risk factors associated with mortality included race/ethnicity (Hispanic HR adj vs. non-Hispanic white participants 0.70; 95% CI 0.53-0.94; P = 0.02), being older (HR adj 1.02 per year of age; 95% CI 1.01-1.03; P < 0.001), having less education, having a lower enrolment CD4 Tcell count (HR adj 0.86 per 100 cells/lL; 95% CI 0.80-0.92; P < 0.001), having a higher enrolment HIV viral load (HR adj 1.44 per 1 log 10 copies/mL; 95% CI 1.36-1.54; P < 0.001), having a lower enrolment Karnofsky performance score (HR adj for Karnofsky ≥ 80 = 0.81; 95% CI 0.67-0.98; P = 0.04), weighing less (HR adj per 10 kg Seven hundred and ninety-four participants had enrolment plasma HIV viral loads < 2.6 log 10 copies/mL and were considered to be "virologically suppressed" for HIV. Risk factors for mortality among these participants (Tables 2 and 3 ) included public insurance (HR adj for Medicare 1.93; 95% CI 1.08-3.44; P = 0.02 and HR adj for Medicaid 2.09; 95% CI 1.02-4.27; P = 0.04) vs. private insurance, older age (HR adj = 1.05 per year of age; 95% CI 1.01-1.07; P = 0.005), hypertension (HR adj 1.80; 95% CI 1.07-3.03; P = 0.03), renal disease (HR adj 2.03; 95% CI 1.09-3.77; P = 0.02), and being enrolled earlier in the study (HR adj 0.90 per calendar year of enrolment; 95% CI 0.82-0.98; P = 0.02).
Participants with health care insurance tended to remain insured with the same insurance category throughout the study. Among privately insured persons at enrolment who were alive at the end of the study, 73% had private insurance at the end of the study, and 14% Medicare; among privately insured persons at enrolment who died during the study, 65% had private insurance at the visit just prior to death, and 19% Medicare. Among persons with Medicare at enrolment who were alive at the end of the study, 75% had Medicare at the end of the study, and 9% private insurance; among persons with Medicare at enrolment who died, 77% had Medicare and 8% Medicaid at the visit prior to death. Among persons with Medicaid at enrolment who were alive at the end of the study, 50% had Medicaid and 30% Medicare at the end of the study; among persons with Medicaid at enrolment who died during the study, 60% had Medicaid and 24% Medicare at the visit just prior to death. Among persons who were uninsured at enrolment and were alive at the end of the study, only 31% were uninsured at the end of the study, and among those who died, only 36% were uninsured at the visit prior to death. The proportions of participants who were uninsured at enrolment but had subsequent insurance were 12% for private insurance, 29% for Medicare and 20% for Medicaid at the end of the study for those alive at the end of the study and 8% for private insurance, 25% for Medicare and 21% for Medicaid at the visit prior to death for those who died during the study. Because of changes in insurance status during the study, a time-updated analysis of insurance vs. mortality was performed ( Fig. 1 KaplanÀMeier estimates of mortality. retinitis at presentation (Table 1) , as evidenced by larger lesions and more posteriorly located lesions [26] . In the adjusted analysis, the results were not significantly different among the four insurance groups (Table 5) .
Discussion
The LSOCA cohort study is unique among cohort studies of HIV-infected persons in the USA in that it CI, confidence interval; HR adj , adjusted hazard ratio; MSM, men who have sex with men; IDU, injecting drug use; cART, combination antiretroviral therapy. Hazard ratios were adjusted for age, race/ethnicity, gender, education, HIV transmission category, insurance status, combination antiretroviral therapy use, CD4 T-cell count, nadir CD4 T-cell count prior to enrolment, HIV viral load, maximum HIV viral load prior to enrolment, Karnofsky performance score, cytomegalovirus retinitis, hepatitis C virus serostatus, hypertension, diabetes, hyperlipidaemia, renal disease, anaemia, year of enrolment and weight. *Insurance status: the private insurance category included those with and without other insurance, and the Medicare category included those with Medicare with and without Medicaid.
enrolled only participants with late-stage HIV disease (i.e. AIDS) and from all HIV risk groups (as opposed to single risk group or single gender studies) [13] . Hence, the LSOCA provides important information on patients with late-stage HIV disease and on those who present with AIDS. Our data suggest that publicly insured persons with AIDS have a greater risk for mortality than privately insured persons. In the entire cohort, there was significantly greater mortality in the unadjusted and adjusted analyses among Medicare recipients and in the unadjusted analysis among Medicaid recipients when compared with privately insured persons. Among participants with a suppressed plasma HIV viral load at enrolment, mortality in both the unadjusted and adjusted analyses was greater among both Medicare and Medicaid recipients compared with privately insured persons, and in the time-updated analysis there was greater mortality associated with these same insurance types. The seemingly paradoxical result that the uninsured had a similar mortality risk to privately insured persons appears to be explained by uninsured persons obtaining insurance during the study, their similar access to ART, and their lower burden of comorbidities at enrolment. In the USA, uninsured HIV-infected patients often obtain ART through the Ryan White HIV/AIDS Program, which provides primary medical care and treatment for HIV-infected persons who are uninsured or underinsured [31] . In the time-updated analysis, being uninsured was associated with greater mortality than having private insurance. During the period covered by LSOCA, estimates of the uninsured in the USA increased from~16 to~19% of the population [32, 33] , so that LSOCA's 16% uninsured was similar to that of the USA as a whole.
Other risk factors for mortality included coinfection with HCV, CMV retinitis, lower CD4 count, higher plasma HIV viral load, older age, lower body weight, and the age-related comorbidities of hypertension and renal disease. Mortality decreased throughout the calendar period during which the study was conducted, as evidenced by the decline in mortality with later year of study entry, consistent with the advances in and increased options for ART.
CMV retinitis management requires close follow-up, management of potentially toxic drugs, and coordination of the care provided by ophthalmology and infectious disease physicians [20] [21] [22] [23] 34] . We therefore evaluated bilateral visual impairment among patients with CMV retinitis as a marker of quality of care, and after adjustment for baseline imbalances in the severity of CMV retinitis [26] , there were no significant differences among the four insurance groups. Because there were no differences in the outcome of the complicated management of CMV retinitis, insurance-related differences in mortality may not reflect differences in access to or process of care, but may reflect 'burden of disease-related factors'. In this regard, patients with Medicare and Medicaid had lower enrolment Karnofsky performance scores, greater percentages of disabled persons, and greater proportions with HCV infection. Patients with Medicare had more non-AIDS-related comorbidities, including hypertension, diabetes and renal disease. Finally, participants with Medicare and, to a lesser extent, Medicaid appeared to have a less robust response to ART, as evidenced by a slower rate of rise of CD4 counts after initiation of ART. All participants in LSOCA had AIDS, not earlier stages of HIV infection, so the results may not be generalizable to the entire HIV epidemic. Because of an interest in ocular outcomes, the cohort was enriched for CMV retinitis [6, 13, [20] [21] [22] 35] ; hence, LSOCA may not represent the AIDS epidemic as it exists today, with a reduced incidence of CMV disease [36] . However, the LSOCA cohort is the only prospective cohort of patients with AIDS (as opposed to earlier stages of HIV infection) including all HIV transmission risk groups in the USA [13] , and therefore provides important information on outcomes in latestage HIV disease (i.e. AIDS). Furthermore, the LSOCA cohort's demographic characteristics are similar to those of the AIDS epidemic, except for a slightly lower proportion of participants with a history of injecting drug use, suggesting overall good generalizability to persons with AIDS [13] . Although one goal of ART is to prevent the progression of HIV infection to AIDS, late diagnosis of HIV infection and difficulties in achieving viral suppression for all patients, even among patients retained in care, suggest that many HIV-infected persons will progress to AIDS [37, 38] . Furthermore, among HIV-infected persons, mortality is higher among persons who initiate cART late in the course of HIV infection compared with those who initiate cART at higher CD4 counts. Additionally, among persons who initiate cART with advanced HIV disease, a subset may not achieve immune reconstitution, as evidenced by less robust increases in CD4 counts, resulting in a greater risk of mortality [39, 40] . One study suggested that cART may be initiated at lower CD4 counts among persons with Medicare or Medicaid than among privately insured persons [41] , which could contribute to differences in mortality.
Our definition of suppressed plasma HIV viral load was based upon the detection threshold of the assay used at the start of LSOCA. Newer assays detect much lower levels of HIV replication and provide more precision regarding HIV replicative activity. Nevertheless, our findings regarding mortality rates by insurance status among participants with "suppressed" HIV viral loads mirror the findings of the entire cohort, suggesting that use of more recent HIV viral load assays and definitions of "virological suppression" would not alter the conclusions. Although we collected information on non-AIDS-related comorbidities, data regarding cardiovascular disease were incomplete, as collecting detailed cardiovascular disease data began only after 80% of the cohort had been enrolled. Because there was no opportunity to collect the data for participants who died early in the study, having missing cardiovascular disease data was a risk factor for mortality, and cardiovascular disease could not be included in the adjusted model. Nevertheless, we did have data regarding risk factors for cardiovascular disease, including hypertension, hyperlipidaemia and diabetes, and included all of these in the adjusted models. Finally, we did not have detailed data on potential insurancerelated barriers to accessing care, such as co-pays and deductibles.
Our data complement and extend the observations in the HIV Outpatient Study (HOPS) regarding the relationship between health insurance and mortality, as we have reported increased mortality among patients with AIDS and among patients with and without HIV virological suppression. The HOPS analysis evaluated only persons with suppressed HIV load. We evaluated CMV retinitis outcomes as a marker for process of care and, after adjustment for baseline differences, could not detect a difference among the four groups.
Health care insurance status has been associated with mortality and worse outcomes among persons with lung cancer, Hodgkin disease, vascular disease and renal disease; in these studies, patients with public insurance (particularly Medicaid) or who were uninsured had worse outcomes than those with private insurance [42] [43] [44] [45] [46] [47] . Many studies demonstrate more advanced disease and a higher rate of comorbidities among persons with public or no insurance, accounting at least in part for the differences in outcomes [42] [43] [44] [45] [46] [47] , but some studies demonstrate a persistently worse outcomes for those with public or no insurance even after adjustment, suggesting access to care or process of care issues [42, 46, 47] . In LSOCA, the rate of noninfectious, age-related comorbidities was greater among those with public insurance, accounting at least in part for the difference in mortality. Although participants in LSOCA who were uninsured at enrolment had a similar mortality rate to privately insured participants, our data suggest that these patients accessed care (e.g. ART) and often obtained insurance. These findings, plus their lower frequency of noninfectious, age-related comorbidities, may account for any differences between our results and those obtained in other studies for other diseases. Consistent with this interpretation is the greater mortality among those in LSOCA who remained uninsured in the time-updated analysis.
In conclusion, our data suggest greater mortality among persons with AIDS in the USA who have publicly funded health care insurance, both Medicare and Medicaid, compared with private health care insurance. These differences may reflect differences in non-HIV-related comorbid disease burden, particularly age-related diseases, the diagnosis and prevention of which should be undertaken routinely and the management of which should be pursued aggressively. Although we did not detect differences in one outcome related to the process of care, we cannot exclude insurance status as an independent risk factor. Future research should evaluate insurance status as a potential marker for access-to-care barriers.
